Introduction
Anaemia is a common feature of chronic kidney disease (CKD) and when untreated is strongly associated with poor outcomes resulting in increased hospitalisations and mortality. This chapter describes analyses of the management of anaemia in dialysis patients in the UK in 2015.
A number of clinical practice guidelines exist for the management of anaemia in patients with CKD. The Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease was published in August 2012 [1] . Commentaries and position statements on this document were made by both the Kidney Disease Outcomes Quality Initiative (KDOQI), and the European Renal Best Practice Guidelines Group (ERBP) [2, 3] . The Renal Association Clinical Practice Guideline for Anaemia of CKD (5th edition) was published in 2010 with the 6th edition expected in 2017 [4] . The National Institute for Health and Care Excellence (NICE) Clinical Guideline on Chronic Kidney Disease: Managing Anaemia was published in June 2015, mid-way through the data collection period [5] .
This chapter reports on the analyses of data items collected by the UK Renal Registry (UKRR) measured against the audit parameters set in the Renal Association Clinical Practice Guideline (5th edition) [4] . Table 7 .1 lists the audit measures recommended in these guidelines alongside those parameters measured in this chapter and reasons for exclusion.
Methods
Most of the analyses in this chapter use the incident or prevalent renal replacement therapy (RRT) cohorts for 2015. Some analyses use data from earlier years. Haemoglobin levels are given in g/L as the majority of UK laboratories have now switched to reporting using these units rather than g/dl. Ford/Gilg/Williams
The UKRR extracted quarterly data electronically from renal centres in England, Wales and Northern Ireland (E,W&NI) taking the latest available result from each quarter. Data from Scotland were provided by the Scottish Renal Registry (SRR).
For the analyses of Hb for incident patients, those patients commencing RRT on PD or HD were included whilst those receiving a pre-emptive transplant were excluded. Hb measurements from after starting dialysis but still within the same quarter of the year were used. Therefore, depending on when in the quarter a patient started RRT the Hb data could be from zero to 90 days later. Due to possible deficiencies with extract routines it is possible that a small number of the values extracted electronically may actually be from before the person started dialysis. This problem will not occur for Scottish data. Patients who died within the first 90 days on treatment were excluded. Results are also shown with the cohort subdivided into early and late presenters (date first seen by a nephrologist, 90 or more days and less than 90 days before starting dialysis respectively). For these analyses only centres with at least 75% completeness of presentation time data were included.
For the analyses of prevalent dialysis patients those patients receiving dialysis on 31st December 2015 were included if they had been on the same modality of dialysis in the same centre for at least three months. In order to improve completeness, the last available measurement for each patient from the last two quarters was used for Hb and from the last three quarters for ferritin.
The completeness of data items was analysed at both centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from the caterpillar and funnel plots showing centre level results. Centres providing relevant data from less than 10 patients were also excluded from the plots. The number preceding the centre name in the caterpillar plots is the percentage of patients who have data missing.
Summary statistics including minimum, maximum, interquartile ranges (IQR), averages (mean and median) and standard deviations were calculated. The median values and the IQRs are shown using caterpillar plots. The percentages achieving standards were also calculated and these are displayed using caterpillar plots with the percentages meeting the targets and 95% confidence intervals (CIs) shown. Funnel plots show the distribution of the percentages meeting the targets and also whether any of the centres were significantly different from the average. Longitudinal analyses were performed to show overall changes in achievement of standards over time.
Erythropoietin data from the last quarter of 2015 were used to define which patients were receiving erythropoietin stimulating agents (ESAs). Scotland was excluded from this analysis as data about ESAs were only available for May (and average doses over the year were used here -see later). Each individual was defined as being on ESA if a drug type and/or a dose was present in the data. Centres reporting fewer than 60% of HD patients or fewer than 40% of PD patients being treated with ESAs were considered to have incomplete data and were excluded from further analysis. It is recognised that these exclusion criteria are relatively arbitrary but they are in part based upon the frequency distribution graph of centres' ESA use as it appears in the data. The percentage of patients on ESAs was calculated from these data and incomplete data returns risk seriously impacting on any conclusions drawn.
For analyses of ESA dose, values are presented as weekly erythropoietin dose. Doses of less than 150 IU/week (likely to be darbepoietin) were harmonised with erythropoietin data by multiplying by 200. No adjustments were made with respect to route of administration. Patients who were not receiving ESAs were not included in analyses of dose (rather than being included with dose = 0). Many centres provided data on ESA dose but not on ESA frequency. The ESA dose field is defined as the weekly dose and the dose is presumed to have been converted accordingly on submission to the UKRR. This may be an incorrect assumption for a number of patients and this needs to be considered when interpreting the ESA information.
Starting with the cohort of patients receiving ESAs in the final quarter of the year and having a dose value present for that quarter, any further dose values available from the earlier three quarters of the year were used (provided the patient was on the same treatment and receiving the same drug in those quarters). The average (mean) of the available values was then used in analyses rather than the dose in the final quarter.
The ESA data were collected electronically from renal IT systems but in contrast to laboratory linked variables the ESA data required manual data entry. The reliability depended upon the data source, whether the entry was linked to the prescription or whether the prescriptions were provided by the primary care physician. In the latter case, doses may not be as reliably updated as the link between data entry and prescription is indirect.
Results

Anaemia management in incident dialysis patients Haemoglobin in incident dialysis patients
As the UKRR does not collect comprehensive data on patients who are not yet receiving RRT Hb at the time of starting RRT is the only indication of concordance with anaemia clinical practice guidelines in the pre-dialysis (CKD not (yet) on dialysis) group. The percentage data returned and outcome Hb are listed in table 7.2. Cambridge was unable to submit any data prior to closing the database. About 33% of Sheffield's incident patients' data were entirely missing from the data extracts, including all their late presenters, so the cohort included is possibly not representative of all their incident dialysis patients. Stevenage did not submit any Hb data except for the first quarter of the year. The cause of this extraction problem has now been resolved and Stevenage are submitting Hb data for 2016.
The median Hb of patients at the time of starting dialysis in the UK in 2015 was 98 g/L. The median Hb for patients at the time of starting dialysis by renal centre is shown in figure 7.1. The percentage of patients starting dialysis with Hb 5100 g/L is shown in figure 7.2. Using data from centres with adequate completeness for date of first presentation the difference in median Hb between early (100 g/L) and late (92 g/L) presenters is shown in Anaemia Management in UK dialysis patients Ford/Gilg/Williams Incident dialysis patients from 2014 were followed for one year and the median haemoglobin and percentage with 5100 g/L in survivors on the same treatment at the same centre were calculated for each quarter. Only patients with Hb data for each of the four time points were included in this analysis. Results by modality and length of pre-dialysis care are shown in figures 7.3 and 7.4. The 'PD-late' group consisted of only 30 patients so care should be taken in interpreting the results.
The distribution of Hb ranges in incident dialysis patients by year of start is shown in figure 7 .5. The proportion of incident dialysis patients with Hb 5120 g/L has fallen from 17.2% in 2006 to 8.4% in 2015. In contrast, the proportion of patients starting dialysis with Hb ,100 g/L has increased from 40.0% in 2006 to 53.2% in 2015.
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Haemoglobin in prevalent peritoneal dialysis patients
The median Hb of patients on PD in the UK in 2015 was 112 g/L (IQR 103-120, table 7.5). For PD patients 81% had a Hb 5100 g/L. Figure 7 .12 shows the median Hb in PD patients by centre. 
Relationship between Hb in incident and prevalent dialysis patients
The relationship between the percentage of incident and prevalent patients with Hb 5100 g/L is shown in figure 7 .17. As expected, all centres had a higher percentage of prevalent patients achieving a Hb 5100 g/L than of incident patients.
Changes in achievement of Hb 5100 g/L by year of start in both incident and prevalent patients is shown in figure 7 .18. This shows a continuing fall in the proportion of patients achieving a Hb 5100 g/L over the last decade.
Ferritin in prevalent haemodialysis patients
The median and IQR for serum ferritin for patients treated with HD are shown in figure 7 
Ferritin in prevalent peritoneal dialysis patients
The median and IQR for serum ferritin for patients treated with PD are shown in figure 7 .23. The percentages with serum ferritin 5100 mg/L, .100 mg/L to 4500 mg/L, and 5800 mg/L are shown in figures 7.24, 7.25 and 7.26 respectively. The median serum ferritin in PD patients was 295 mg/L with 88% of PD patients achieving a serum ferritin 5100 mg/L.
Erythropoiesis stimulating agents in prevalent haemodialysis patients
The median dose of ESA for prevalent HD patients in England, Wales and Northern Ireland was 7,500 IU/week with wide variation between centres from 4,833 IU/week (York) to 13,267 IU/week (Newcastle) (table 7.4). There was very little correlation between median ESA dose and either median Hb (figure 7.27) or compliance with Hb 100-120 g/L (figure 7.28). For these analyses only patients with both Hb and ESA data were included.
Erythropoiesis stimulating agents in prevalent peritoneal dialysis patients
The median dose of ESA for prevalent PD patients in England, Wales and Northern Ireland was 4,000 IU/week (table 7.5).
ESA prescription and association with achieved haemoglobin consensus was that these patients should not be included in the group of patients not meeting this target. There are two reasons: first, the high Hb remains largely outside the control of the clinician; secondly, the trials suggesting it may be detrimental to achieve a high Hb in renal patients were based upon patients treated with ESAs [6] [7] [8] . .120 g/L and 11.8% had a Hb .120 g/L and were not receiving ESAs.
ESA prescription: age and modality associations The proportion of patients on ESA was higher for HD (88%) than for PD (69%). This difference was maintained across all age groups (figure 7.31). The proportion of patients with Hb 5100 g/L without requiring an ESA is shown (by age group and modality) in figure 7 .32.
ESAs and time on renal replacement therapy
The percentage of patients on ESA by time on RRT and dialysis modality is shown in figure 7 .33. This is a Patients who had previously changed RRT modality were included in the analysis. The proportion of PD patients receiving ESA rises with duration of RRT from 65% after 3-12 months to 84% after 10 or more years.
Resistance to ESA therapy
The Renal Association guidelines define resistance to ESA therapy as 'failure to reach the target Hb level despite sc epoetin dose >300 IU/kg/week (450 IU/kg/ week iv epoetin) or darbepoetin dose >1.5 mcg/kg/ week' [4] . Figure 7 .34 shows the frequency distribution of weekly ESA dose adjusted for weight by treatment modality. Centres included in this analysis were restricted to those with good completeness for weight (.75%) and ESA data. Thirty three centres were included for HD data and 20 centres for PD. The prevalence of PD patients receiving over 300 IU/kg/week was 1.6% with 6.1% of HD patients receiving more than 300 IU/kg/week and 1.1% more than 450 IU/kg/week. Table 7 .6 shows that the percentage of all patients treated with an ESA and having Hb .120 g/L ranged between 6-27% for HD and between 0-27% for PD. Table 7 .7 shows the percentage completeness for ESA type, dose, route and frequency for centres reporting ESA data. Even for this group of centres which is already restricted to those with useable ESA data, completeness of frequency and administration route average below 50%. Roughly half of the centres have very good completeness for these items and the other half did not submit at all.
Discussion
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Since the introduction of ESAs in the 1980s the management of renal anaemia has changed markedly, from the general acceptance of severe anaemia punctuated by intermittent blood transfusions, to the maintenance of acceptable Hb concentrations for patients with CKD.
The understanding of what constitutes an acceptable Hb range has evolved with the published literature and is illustrated by the historic analyses in figures 7.18 and 7.35. These figures show a steady increase in Hb until the middle of the last decade followed by a steady fall during the last ten years. This change in trend followed the publication of the CHOIR and CREATE studies in 2006 which unexpectedly showed adverse outcomes from the physiological correction of haemoglobin with ESAs [6] [7] . These findings were supported by the TREAT study in 2009 [8] .
Haemoglobin outcomes were similar for both HD and PD patients with proportions of prevalent patients compliant with Hb 100-120 g/L of 59% and 57% respectively. Prevalent HD patients had a higher median serum ferritin (415 mg/L vs 295 mg/L), a higher proportion of patients requiring ESAs (88% vs 69%) and a higher median ESA dose in those receiving ESAs (7,500 IU/week vs 4,000 IU/week) compared with prevalent PD patients.
As expected, a greater proportion of prevalent patients than incident patients attained a Hb 5100 g/L (80% vs 47%). Only 34% of late presenters achieved a Hb 5100 g/L suggesting that part of this difference is because there was less opportunity for anaemia to be treated with iron or ESAs. The fact that even in the early presenting incident group of patients only 51% achieved Hb 5100 g/L suggests that opportunity is only part of the explanation for incident patients. Alternative explanations include the fact that a number of patients commence dialysis at the time of an acute illness when acute anaemia is common.
The proportion of patients achieving a serum ferritin of 5100 mg/L was 94% of HD patients and 88% of PD patients.
The NICE guideline on managing anaemia was published mid-way through the data collection period [5] and there are some fundamental differences between these and the previous Renal Association guideline, especially with respect to measurements of iron status. Specifically, the new NICE guidance recommends that percentage hypochromic red blood cells or reticulocyte haemoglobin are preferable markers of iron deficiency than serum ferritin or transferrin saturation. Renal centres will need to consider the incorporation of these changes into local guidelines as well as the need to ensure electronic collection of these data items. Assuming these recommendations are incorporated into the revised RA anaemia guidance, these additional iron indices will then need to be added to the UKRR dataset.
The analysis of ESA usage was limited by incomplete data returns. From the available data, 88% of HD patients and 69% of PD patients were receiving ESAs. The attainment of Hb targets correlated poorly with median ferritin and ESA usage.
There continued to be variation in concordance with anaemia guidelines between UK renal centres.
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